Cure Pharmaceutical Holding Corp. (CURR) financial statements (2023 and earlier)

Company profile

Business Address 1620 BEACON PLACE
OXNARD, CA 93033
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
3/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 1,7254,0965011081,1065
Cash and cash equivalents 1,7254,0965011081,1065
Receivables 22414210347 
Inventory, net of allowances, customer advances and progress billings 4491563845811
Inventory 4491563845811
Prepaid expense  489465872242
Deferred costs  615    
Other undisclosed current assets 1,4521,131    
Total current assets: 3,8506,1881,5887441,4187
Noncurrent Assets
Finance lease, right-of-use asset 5260
Operating lease, right-of-use asset 34363
Property, plant and equipment 2,0746413003373717
Intangible assets, net (including goodwill) 15,57910,9861,206900895 
Goodwill 13,8689,178    
Intangible assets, net (excluding goodwill) 1,7111,8081,206900895 
Deferred costs    13  
Other undisclosed noncurrent assets 24,46114,522302104152 
Total noncurrent assets: 42,50926,2721,8081,3551,4177
TOTAL ASSETS: 46,35932,4603,3962,1002,83514
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 3,4341,4831,283675292 
Accounts payable 2,1351,260774545265 
Accrued liabilities 68022350913026 
Employee-related liabilities 308     
Taxes payable 311     
Debt 905609501,551594
Asset retirement obligation     (9) 
Due to related parties 1,040     
Other undisclosed current liabilities 9,08810,2936,3181,303216 
Total current liabilities: 14,46711,8368,5523,5295584
Noncurrent Liabilities
Long-term debt and lease obligation 7,01050    
Long-term debt, excluding current maturities 7,010     
Finance lease, liability  50
Other undisclosed noncurrent liabilities 3,6037,067 560560 
Total noncurrent liabilities: 10,6137,117 560560 
Total liabilities: 25,08018,9538,5524,0891,1184
Stockholders' equity
Stockholders' equity attributable to parent, including: 21,27913,507(5,172)(2,036)1,71710
Common stock 60382724237
Additional paid in capital 101,80763,03523,42516,48412,41217
Accumulated deficit (81,253)(50,632)(29,269)(18,869)(10,719)(14)
Other undisclosed stockholders' equity attributable to parent 6651,066646325  
Stockholders' equity attributable to noncontrolling interest   1647  
Total stockholders' equity: 21,27913,507(5,155)(1,989)1,71710
TOTAL LIABILITIES AND EQUITY: 46,35932,4603,3962,1002,83514

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
3/31/2016
Revenues 2,0516235841808411
Revenue, net1718111
Cost of revenue (1,076)(231)(280)(181)(153)(1)
Cost of goods and services sold   (280)(181)(153)(1)
Deferred policy acquisition costs, amortization expense  (427)    
Other undisclosed gross profit      (1)
Gross profit: 975392304(0)(69)10
Operating expenses (19,933)(14,084)(7,862)  (21)
Other undisclosed operating loss    (7,342)(3,857) 
Operating loss: (18,958)(13,692)(7,558)(7,342)(3,926)(10)
Nonoperating expense (11,413)(7,940)(2,873)(822)(231) 
Other nonoperating expense (11,663)(7,681)(2,873)(822)(231) 
Interest and debt expense (65)4,111(3,037)(1,582)(122) 
Loss from continuing operations before equity method investments, income taxes: (30,436)(17,521)(13,468)(9,746)(4,279)(10)
Income from equity method investments 22     
Other undisclosed income (loss) from continuing operations before income taxes (207)(3,852)3,0371,582121 
Loss from continuing operations before income taxes: (30,621)(21,373)(10,431)(8,164)(4,157)(10)
Other undisclosed loss from continuing operations  (110)    
Loss before gain (loss) on sale of properties: (30,621)(21,483)(10,431)(8,164)(4,157)(10)
Other undisclosed net income  120    
Net loss: (30,621)(21,363)(10,431)(8,164)(4,157)(10)
Net income attributable to noncontrolling interest  21,3733014  
Other undisclosed net loss attributable to parent  (21,373)(30)   
Net loss attributable to parent: (30,621)(21,363)(10,431)(8,150)(4,157)(10)
Other undisclosed net income available to common stockholders, basic   30   
Net loss available to common stockholders, diluted: (30,621)(21,363)(10,400)(8,150)(4,157)(10)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
3/31/2016
Net loss: (30,621)(21,363)(10,431)(8,164)(4,157)(10)
Comprehensive loss: (30,621)(21,363)(10,431)(8,164)(4,157)(10)
Comprehensive income, net of tax, attributable to noncontrolling interest  21,3733014  
Comprehensive income (loss), net of tax, attributable to parent: (30,621)10(10,400)(8,150)(4,157)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: